Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of IcoSema vs Individual Components in Type 2 Diabetes
NCT03789578Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2019
- Primary completion
- Oct 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of icosema in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the serum insulin 287 concentration-time curve from 0 hours to last quantifiable observation and Area under the plasma semaglutide concentration-time curve from 0 hours to last quantifiable observation. Started Jan 2019; status: completed.
02
Drugs
icosema
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03789578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03789578.